AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 11 min read

Ascendiant Capital maintains Buy rating on SINTX Technologies, $12.50 price target

Ascendiant Capital maintained a Buy rating on SINTX Technologies with a $12.50 price target, implying 460.5% upside from the Sep 30 close of $2.23. The firm cited strong growth potential in the orthopedic device market and attractive valuation.

Original reporting
tradingview.com
Published Oct 1, 2026, 9:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 9:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ascendiant Capital maintains Buy rating on SINTX Technologies, $12.50 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could attract new capital and drive short‑term price appreciation.

02

Market read

A fresh analyst upgrade with a high price target may trigger buying pressure in SINTX.

03

What to watch

Potential regulatory or reimbursement hurdles for orthopedic devices.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst note from Ascendiant Capital providing a new buy rating and price target.

Market effects

Sector

Highlights growth potential in the orthopedic device market, may lift peers.

Regional

Limited to U.S. micro‑cap investors.

Global

Low; primarily affects SINTX shareholders.

Counterpoint

What could challenge this read

The target may be overly optimistic given the company's size and execution risk.

Key entities

  • analyst
    Ascendiant Capital

    Research firm issuing the buy rating and price target.

  • company
    SINTX Technologies

    Micro‑cap orthopedic device developer.

Read at source← All news

Related articles

OCT 1
$SINTMed

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone

SEC EDGAR 8-K2 min
AUG 11
$SINTLow

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives SALT LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a

SEC EDGAR 8-K2 min
JUN 4
$SINTLow

Sintx Technologies (NASDAQ:SINT) Given “Buy” Rating at Maxim Group

Maxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.

dailypolitical.com4 min
OCT 1
$LLYHigh

BMO reiterates Eli Lilly stock Outperform on TRIUMPH-2 data

BMO Capital reiterated an Outperform rating on Eli Lilly (LLY) with a $1,400 price target, citing strong TRIUMPH-2 data for Reta. The company's stock has surged 41% over the past year, with revenue up nearly 50%. Recent FDA approvals for Onswik and Inluriyo, along with positive analyst outlooks, underscore Eli Lilly's growth prospects.

investing.com2 min
OCT 1
$MCKMed

McKesson extends CVS deal; shares rise

McKesson (MCK) shares rose 4.4% after extending its pharmaceutical distribution agreement with CVS Health to 2032. The company reaffirmed its FY2027 EPS guidance of $44.20-$45.00 and long-term EPS growth target of 13-16%. Details will be discussed in its Q2 FY2027 earnings call.

investing.com1 min